Haleon and the University of Sydney drive new osteoarthritis research

• Haleon is teaming up with the University of Sydney to launch a five-year fellowship to research the efficacy of dietary supplements for osteoarthritis  

• The collaboration will develop innovative, evidence-based strategies to help improve osteoarthritis management in Australia, and globally 

• Osteoarthritis is a painful and debilitating condition that affects over 2 million Australians, representing a significant public health burden, a leading cause of disability and reduced quality of life¹ 

Tuesday 8 October, Sydney, Australia: Leading consumer healthcare company Haleon is sponsoring a five-year named fellowship program at the University of Sydney that will investigate the therapeutic role of supplements in managing osteoarthritis symptoms and digital health technologies that improve mobility. 

Osteoarthritis is a leading cause of disability affecting over 2 million Australians¹ and 595 million people globally.² It represents a significant public health burden that diminishes quality of life among ageing populations. 

The fellowship will fund a postdoctoral researcher to work under the guidance of world leading osteoarthritis expert, rheumatologist and researcher Professor David Hunter (link to biography).  

Professor Hunter said the research collaboration represents a shared focus and investment in improving osteoarthritis management: “This is a disabling disease that has a huge impact on the people affected.”  

“A collaborative effort between researchers and manufacturers will drive innovation and hopefully improve the lives of those impacted by this devastating disease. Use of supplements and natural ingredients in managing osteoarthritis is an exciting area with a lot of potential. I’m not aware of any other long-term, five-year projects of this nature that has osteoarthritis as its focus,” said Hunter.  

Haleon, the makers of well-known consumer health products like Panadol, Voltaren, Centrum and Caltrate, and the University of Sydney are excited to come together with the shared goal of finding better management strategies for osteoarthritis and developing better outcomes for the people affected.  

Dr Bincy Thampi, Medical & Scientific Affairs Lead at Haleon ANZ, says the fellowship is consistent with Haleon’s commitment to science and innovation in consumer healthcare.  

“As global leaders in pain management and everyday health, Haleon has a strong commitment to scientific research that drives innovative self-care and improves consumer health outcomes. This partnership illustrates Haleon’s commitment to advancing trusted science for our products to better everyday health and we’re excited to see where this partnership with University of Sydney leads,” said Thampi.   

ENDS